Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Threshold completes $18.3 million private financing

This article was originally published in Scrip

Executive Summary

Threshold Pharmaceuticals has completed an $18.3 million private placement of its common stock and warrants after receiving shareholder approval. Threshold has sold nearly nine million shares of its common stock at $2.04 per share, and warrants to purchase up to about 3.6 million shares of its common stock. Net offering proceeds of the placement were around $17 million. The funds will help Threshold to study the activity of its hypoxia-activated prodrug TH-302 for the treatment of solid tumours in at least four different combination clinical trials against multiple tumour types, the company said. Investors in Threshold included Sutter Hill Ventures, HealthCare Ventures, LLC, Alta Partners and Three Arch Partners.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

SC004236

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel